Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

68.54USD
19 Jul 2019
Change (% chg)

$0.29 (+0.42%)
Prev Close
$68.25
Open
$68.20
Day's High
$68.81
Day's Low
$68.10
Volume
2,301,216
Avg. Vol
1,971,950
52-wk High
$100.23
52-wk Low
$65.06

Latest Key Developments (Source: Significant Developments)

Abbvie Enhances Early Stage Oncology Pipeline With Acquisition Of Mavupharma
Monday, 15 Jul 2019 

July 15 (Reuters) - AbbVie Inc ::ABBVIE ENHANCES EARLY STAGE ONCOLOGY PIPELINE WITH ACQUISITION OF MAVUPHARMA.ABBVIE INC - FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED..ABBVIE - ACQUIRED MAVUPHARMA, A PRIVATELY HELD BIOPHARMACEUTICAL CO FOCUSED ON NOVEL APPROACHES TO TARGET STING PATHWAY FOR TREATMENT OF CANCER.  Full Article

Abbvie Announces FDA Approval Of Venclexta For Previously Untreated Chronic Lymphocytic Leukemia Patients
Wednesday, 15 May 2019 

May 15 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES US FDA APPROVAL OF VENCLEXTA® (VENETOCLAX) AS A CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.APPROVAL BASED ON DATA FROM PHASE 3 CLL14 TRIAL OF VENCLEXTA.DATA FROM CLL14 TRIAL IS EXPECTED TO BE PRESENTED AT AN UPCOMING MEDICAL MEETING AND PUBLISHED IN A JOURNAL THIS YEAR..  Full Article

Abbvie Resolves Humira (Adalimumab) U.S. Patent Litigation With Boehringer Ingelheim
Tuesday, 14 May 2019 

May 14 (Reuters) - AbbVie Inc ::ABBVIE RESOLVES HUMIRA (ADALIMUMAB) U.S. PATENT LITIGATION WITH BOEHRINGER INGELHEIM.ABBVIE INC - ABBVIE WILL GRANT BI A NON-EXCLUSIVE LICENSE TO ITS HUMIRA-RELATED INTELLECTUAL PROPERTY IN UNITED STATES.ABBVIE INC - BI WILL PAY ROYALTIES TO ABBVIE FOR LICENSING ITS HUMIRA PATENTS AND ACKNOWLEDGES VALIDITY AND ENFORCEABILITY OF LICENSED PATENTS.ABBVIE INC - ABBVIE WILL MAKE NO PAYMENTS OF ANY FORM TO BI..ABBVIE INC - U.S. LICENSE FOR BOEHRINGER INGELHEIM WILL BEGIN ON JULY 1, 2023.  Full Article

Abbvie Qtrly Adj EPS $2.14
Thursday, 25 Apr 2019 

April 25 (Reuters) - AbbVie Inc ::ABBVIE QTRLY GAAP EARNINGS PER SHARE $1.65; QTRLY ADJUSTED EARNINGS PER SHARE $2.14.ABBVIE QTRLY NET REVENUE $7.83 BILLION VERSUS $7.93 BILLION.Q1 EARNINGS PER SHARE VIEW $2.05, REVENUE VIEW $7.75 BILLION -- REFINITIV IBES DATA.ABBVIE - QTRLY GLOBAL HUMIRA NET REVENUE OF $4.45 BILLION DECREASED 5.6 PERCENT ON REPORTED BASIS.ABBVIE - IN U.S., QTRLY HUMIRA NET REVENUE OF $3.22 BILLION, UP 7.1 PERCENT.ABBVIE - INTERNATIONALLY, QTRLY HUMIRA NET REVENUE OF $1.23 BILLION DECREASED 27.9 PERCENT ON REPORTED BASIS.ABBVIE SEES 2019 GAAP EPS $7.26 TO $7.36; SEES 2019 ADJUSTED EPS $8.73 TO $8.83.FY2019 EARNINGS PER SHARE VIEW $8.67 -- REFINITIV IBES DATA.ABBVIE - 2019 GAAP EARNINGS PER SHARE GUIDANCE DOES NOT REFLECT A NON-CASH CHARGE FOR CONTINGENT CONSIDERATION RELATED TO APPROVAL OF SKYRIZI.  Full Article

AbbVie Expands Immunology Portfolio With FDA Approval Of Skyrizi™
Tuesday, 23 Apr 2019 

April 23 (Reuters) - AbbVie Inc ::ABBVIE EXPANDS IMMUNOLOGY PORTFOLIO IN THE U.S. WITH FDA APPROVAL OF SKYRIZI™ (RISANKIZUMAB-RZAA) FOR MODERATE TO SEVERE PLAQUE PSORIASIS.ABBVIE INC - SKYRIZI IS EXPECTED TO BE AVAILABLE IN U.S. IN EARLY MAY.  Full Article

Trovagene Announces Positive Data For Onvansertib/Venclexta Combo
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Trovagene Inc ::DATA PROVIDES SUPPORT FOR CLINICAL EVALUATION OF ONVANSERTIB WITH VENETOCLAX IN PATIENTS WITH DIFFICULT-TO-TREAT RELAPSED/REFRACTORY AML.ANNOUNCED DATA THAT EVALUATED EFFECT OF COMBINING ONVANSERTIB WITH VENETOCLAX IN AML CELL MODEL KNOWN TO BE RESISTANT TO VENETOCLAX.DATA FURTHER SUPPORTS TROVAGENE'S ONGOING ONVANSERTIB CLINICAL DEVELOPMENT PROGRAM IN PATIENTS WITH RELAPSED/REFRACTORY AML.CONDUCTING PHASE 1B/2 CLINICAL TRIAL OF ONVANSERTIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY AML AT 9 SITES.  Full Article

British Columbia Pharmacare Lists Abbvie's Hepatitis C Treatment Maviret On Its Formulary
Friday, 22 Mar 2019 

March 22 (Reuters) - AbbVie Inc ::BRITISH COLUMBIA PHARMACARE LISTS ABBVIE'S HEPATITIS C TREATMENT MAVIRET™ ON ITS FORMULARY.ABBVIE INC - BRITISH COLUMBIA PHARMACARE LISTS MAVIRET ON ITS FORMULARY EFFECTIVE MARCH 21, 2019.  Full Article

FDA Warns About Risks Associated With Investigational Use Of Venclexta In Multiple Myeloma
Thursday, 21 Mar 2019 

March 21 (Reuters) - U.S. Food and Drug Administration::FDA WARNS ABOUT THE RISKS ASSOCIATED WITH THE INVESTIGATIONAL USE OF VENCLEXTA IN MULTIPLE MYELOMA.FDA - REVIEWED DATA FROM THE BELLINI CLINICAL TRIAL EVALUATING USE OF VENCLEXTA COMBINED WITH BORTEZOMIB & DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS.FDA - INTERIM TRIAL RESULTS FROM BELLINI CLINICAL TRIAL DEMONSTRATED INCREASED RISK OF DEATH FOR PATIENTS RECEIVING VENCLEXTA VERSUS THE CONTROL GROUP.FDA - PATIENTS TAKING VENCLEXTA FOR AN APPROVED INDICATION SHOULD CONTINUE TO TAKE THEIR MEDICATION AS DIRECTED BY THEIR HEALTH CARE PROFESSIONAL.  Full Article

AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment
Thursday, 7 Mar 2019 

March 7 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES MULTIPLE MILESTONES FOR PHASE 3 CLL14 VENETOCLAX STUDY OF FIXED DURATION TREATMENT IN PREVIOUSLY-UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.ABBVIE INC - FDA HAS ALSO GRANTED VENETOCLAX A FIFTH BREAKTHROUGH THERAPY DESIGNATION (BTD) BASED ON PHASE 3 CLL14 CLINICAL TRIAL.ABBVIE INC - FDA WILL REVIEW APPLICATION UNDER REAL-TIME ONCOLOGY REVIEW (RTOR) PILOT PROGRAM, SIGNALING AGENCY'S INTENTION TO EXPEDITE REVIEW.  Full Article

Voyager Therapeutics And Abbvie Announce Collaboration
Friday, 22 Feb 2019 

Feb 22 (Reuters) - AbbVie Inc ::VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE COLLABORATION TO DEVELOP VECTORIZED ANTIBODIES TO TREAT PARKINSON’S DISEASE AND OTHER SYNUCLEINOPATHIES.VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE $65 MILLION UPFRONT.VOYAGER THERAPEUTICS INC - TO RECEIVE UP TO $245 MILLION IN PRECLINICAL, PHASE 1 OPTION PAYMENTS, POTENTIAL DEVELOPMENT, OTHERS.VOYAGER THERAPEUTICS INC - VOYAGER IS ALSO ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $728 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS.VOYAGER THERAPEUTICS - ELIGIBLE TO RECEIVE TIERED ROYALTIES ON GLOBAL COMMERCIAL NET SALES OF EACH ALPHA-SYNUCLEIN VECTORIZED ANTIBODY.VOYAGER THERAPEUTICS INC - VOYAGER WILL BE RESPONSIBLE FOR RESEARCH, IND-ENABLING AND PHASE 1 CLINICAL ACTIVITIES AND COSTS..VOYAGER THERAPEUTICS - MAY ALSO EARN UP TO A TOTAL OF $500 MILLION IN COMMERCIAL MILESTONES..VOYAGER - ABBVIE HAS OPTION TO LICENSE VECTORIZED ALPHA-SYNUCLEIN ANTIBODY PROGRAM FOR FURTHER CLINICAL DEVELOPMENT AND GLOBAL COMMERCIALIZATION.  Full Article

Photo

Novartis raises full-year targets, aims to settle U.S. lawsuit

ZURICH Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million (£561.7 million) has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.